Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imlunestrant drug-drug interaction study in healthy women
NCT05444556Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of imlunestrant (4 cohorts), sponsored by Eli Lilly and Company. Primary endpoints: Area Under the Concentration Versus Time Curve From Zero to Infinity of Repaglinide at Day 3, Maximum Observed Concentration of Repaglinide at Day 3 and 14 more. Started Jul 2022; status: completed.
02
Drugs
imlunestrant
Beyond the preview
Go deeper on NCT05444556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05444556.